SCHEMBL21362091

SCHEMBL21362091

CC(c1cc(=O)n(C)nc1Cl)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.38
TP53 P04637 2/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
CASP3 P42574 1/20 0.36
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPK13 O15264 1/20 0.35
EIF2AK2 P19525 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
GAA P10253 1/20 0.35
BRD4 O60885 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21362625 0.79 USP2 (0.38) USP2TSHRLMNANPC1TP53
SCHEMBL2896546 0.77 LMNA (0.41) USP2TSHRLMNANPC1NPSR1
SCHEMBL2895355 0.76 USP2 (0.42) USP2TSHRLMNATP53MAPK1
SCHEMBL21362090 0.75 LMNA (0.42) USP2TSHRLMNANPC1TP53
SCHEMBL17718345 0.75 EGFR (0.42) USP2TSHRLMNANPC1TDP1
SCHEMBL14870378 0.75 EGFR (0.42) USP2TSHRLMNANPC1TDP1
SCHEMBL2894014 0.72 LMNA (0.42) USP2TSHRLMNANPC1TP53
SCHEMBL21362092 0.72 LMNA (0.35) LMNANPC1TP53ALDH1A1HTT
SCHEMBL4173841 0.72 KMT2A (0.38) USP2TSHRLMNANPC1TDP1
SCHEMBL15336892 0.72 KMT2A (0.38) USP2TSHRLMNANPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 USP2 4208/4885TSHR 4115/4885LMNA 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.